Add Yahoo as a preferred source to see more of our stories on Google. The FDA has approved two GLP-1 oral medications, including one by Eli Lilly on Wednesday. File Photo by Jim Lo Scalzo/EPA April 1 ...

Eli Lilly (LLY) generated $65.18B in full-year 2025 revenue, up 44.7% year-over-year, driven by its GLP-1 franchises Mounjaro and Zepbound which command 60% of the weight-loss market, with 2026 ...

The U.S. Food and Drug Administration’s approval of Eli Lilly’s once-daily pill orforglipron as a weight loss and obesity treatment this week was the fastest approval of a new medication in decades.

Eli Lilly, the Indianapolis-based pharmaceutical company, officially received approval from the Food and Drug Administration for a new weight-loss pill on April 1. The company shared in a press ...

Eli Lilly has rolled out Foundayo, its oral GLP-1 pill, directly to consumers through its LillyDirect cash-pay channel, as well as to telehealth providers and pharmacies across the U.S. The drug is a ...

CNBC's Angelica Peebles reports the latest news surrounding GLP-1 drugs. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your inbox ...

Eli Lilly stock (LLY) popped by more than 5% on Wednesday after the Food and Drug Administration (FDA) approved the company's new weight-loss pill that Eli Lilly says can be taken "any time of day ...

CNBC's Angelica Peebles reports the latest news surrounding GLP-1 drugs. What a US destroyer shooting a cargo ship's engine out reveals about how the Navy is handling Iran blockade runners VA benefits ...

The U.S. Food and Drug Administration has approved Eli Lilly’s new weight-loss GLP-1 pill, orforglipron, which will be sold as Foundayo. In a clinical trial, participants who received the highest dose ...

The U.S. Food and Drug Administration on Wednesday gave its approval to Eli Lilly’s GLP-1 weight loss pill. The daily pill, called Foundayo, is the second oral GLP-1 product to reach the market over ...